FDA GLP-1 503B Compounding Update — May 2026
On April 30, 2026, the FDA proposed permanently removing semaglutide, tirzepatide, and liraglutide from the 503B outsourcing facility bulks list. The comment period closes June 29, 2026. Here is exactly what changed and what it means for researchers.
What happened
On April 30, 2026, the U.S. Food and Drug Administration announced a formal proposal to exclude semaglutide, tirzepatide, and liraglutide from the Section 503B outsourcing facility bulk drug substances list — permanently closing the primary legal pathway for large-scale compounding of these three GLP-1 class drugs.
The proposal was published in the Federal Register on May 1, 2026 (Docket No. FDA-2024-N-3523). A 60-day public comment period is open through June 29, 2026. This follows the resolution of the national drug shortage designations: the semaglutide shortage was resolved in February 2025, and the tirzepatide shortage was resolved in December 2024.
Understanding the two compounding pathways
503B — Outsourcing facilities (large-scale). FDA-registered facilities that produce large batches of compounded drugs from bulk API without patient-specific prescriptions. They supply compounding pharmacies, telehealth platforms, and clinics at scale. The 503B bulks list is the legal mechanism that allowed this for GLP-1 drugs during the shortage period. The April 30 proposal targets this pathway.
503A — Traditional compounding pharmacies (patient-specific). Licensed pharmacies that compound based on individual prescriptions. Narrow exceptions remain for documented excipient allergies or a need for a dose strength not commercially available. Routine copying of commercial products is prohibited under 503A as well. The April 30 proposal does not directly restrict 503A pharmacies, but it removes the bulk supply pipeline that most 503A compounders rely on for active ingredients.
What the FDA said
FDA Commissioner Marty Makary stated: "When FDA-approved drugs are available, outsourcing facilities cannot lawfully compound using bulk drug substances unless there is a clear clinical need. We carefully reviewed the nominations received and did not identify sufficient evidence to include semaglutide, tirzepatide, and liraglutide on the 503B bulks list."
The "no clinical need" finding is the critical legal determination. The FDA also cited over 455 adverse event reports linked to compounded semaglutide and more than 320 linked to compounded tirzepatide — many involving dosing errors from multidose vials.
Timeline
| Date | Event |
|---|---|
| 2022 | Semaglutide and tirzepatide added to FDA drug shortage list → 503B compounding permitted |
| 2023 | FDA Category 2 peptide restrictions — BPC-157 and 18 others added to "do not compound" list |
| Dec 2024 | Tirzepatide shortage resolved → phased enforcement deadlines begin |
| Feb 2025 | Semaglutide shortage resolved → phased enforcement continues |
| Apr 30, 2026 | FDA proposes formal 503B exclusion of semaglutide, tirzepatide, liraglutide |
| June 29, 2026 | Public comment period closes |
| ~Oct 2026 | FDA expected to finalize rule; CagriSema NDA decision also expected in this window |
What remains open after this proposal
Available after finalization (if proposal is adopted as written):
- FDA-approved branded products: Ozempic, Wegovy, Mounjaro, Zepbound, Victoza, Saxenda
- Manufacturer patient assistance and discount programs
- 503A patient-specific compounding under narrow documented exceptions only
- CagriSema if FDA approved (decision expected Oct–Dec 2026)
- Retatrutide once FDA approved (NDA filing expected Q4 2026)
- Survodutide (GLP-1/glucagon dual agonist) — not directly affected by this proposal
- Cagrilintide standalone — not directly affected
Closed if finalized:
- 503B bulk production of semaglutide, tirzepatide, liraglutide from API
- Large-scale telehealth compounding platforms relying on 503B supply
- Multidose vial formats sourced through 503B facilities
The BPC-157 contrast
While GLP-1 compounding tightens, BPC-157 is moving in the opposite direction. On April 15, 2026, the FDA removed 12 peptides from the Category 2 "do not compound" list. The Pharmacy Compounding Advisory Committee (PCAC) meets July 23–24, 2026 to evaluate whether BPC-157, Semax, Epithalon, and Emideltide should be added to the 503A positive list.
GLP-1 drugs face restrictions because FDA-approved commercial alternatives exist and the national shortages are resolved. BPC-157 faces the opposite regulatory dynamic — no approved commercial form exists, and a positive PCAC recommendation in July could formally legitimize 503A compounding for the first time.
What to watch for
| Date | Event |
|---|---|
| June 29, 2026 | Comment period closes — submissions volume will influence the final rule |
| July 23–24, 2026 | PCAC meeting on BPC-157, Semax, Epithalon — positive regulatory outcome expected |
| Oct–Dec 2026 | FDA final rule on 503B exclusion AND potential CagriSema NDA decision |
| Q4 2026 | Retatrutide NDA filing by Eli Lilly expected |
How to submit public comments
Docket Number: FDA-2024-N-3523
Federal Register: federalregister.gov/documents/2026/05/01/2026-08552
Deadline: June 29, 2026
Compounders, pharmacies, patient advocacy groups, and researchers may submit public comments. The FDA is specifically requesting evidence regarding clinical need for these compounds in compounded form.
Research references
- FDA Federal Register Notice, May 1, 2026 — Docket FDA-2024-N-3523
- FDA — Section 503B Outsourcing Facility Bulk Drug Substances
- FDA — Compounding and Drug Shortages